ArticleCureus2025
Portal Venous Gas After Trans-arterial Radioembolization in Hepatocellular Carcinoma: A Rare but Critical Imaging Finding.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transarterial radioembolization (TARE) is a relatively new treatment option available for unresectable hepatocellular carcinoma (HCC). TARE therapy involves the delivery of radiation directly to the tumor to cause tumor necrosis. Yttrium-90 (Y90) is commonly used as a source of radioembolization in TARE. TARE is very well tolerated and has a low rate of complications. Main complications of TARE for HCC include postembolization syndrome and radiation-induced injury to nearby organs such as the liver, gallbladder, and stomach, causing hepatitis, cholecystitis, or gastric ulceration. A side effect not previously described in TARE literature is portal venous gas after TARE therapy. We present the first ever reported case of portal and variceal venous gas in a 77-year-old male patient who had unresectable HCC and had previously failed chemotherapy. He underwent Y90 TARE for HCC. Following TARE, he presented with right upper quadrant abdominal pain, and imaging showed portal and variceal venous gas. He was treated with antibiotics, with resolution of symptoms and improvement in portal and variceal venous gas on repeat imaging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.